Transdermal delivery formulations patches

In addition to traditional dermal and transdermal delivery formulations, such as creams, ointments, gels, and patches, several other systems have been evaluated. In the pharmaceutical semisolid and liquid formulation area,these include sprays, foams, multiple emulsions, microemulsions, liposomal formulations, transfersomes, niosomes, ethosomes, cyclodextrins, glycospheres, dermal membrane structures, and microsponges. Many of these novel systems use vesicles to modulate drug delivery. Novel transdermal... 

Current androgenic formulations for TRT largely are restricted to injectable formulations of testosterone esters, transdermal delivery formulations (scrotal or nonscrotal patches or gel), or buccal testosterone. Marketed injectable forms of testosterone esters (e.g., testosterone enanthate, propionate, or cypionate) produce undesirable fluctuations in testosterone blood levels, with supraphysiological concentrations early and subphysiological levels toward the end of the period before the next injection. These fluctuations provide an unsatisfactory benefits profile and, in some cases, undesired side effects. Skin patches provide a better blood level profile of testosterone, but skin irritation and daily application limit the usefulness and acceptability of this form of therapy. Oral... 

PG fluxes into the receptor chamber following delivery across hairless mouse skin from formulations (a) and (b) are shown in Figures 3 and 4, respectively. PG association with EPC liposomes [(b)] lowers by one-half the transdermal delivery of the drug when compared to the free patch [(a)]. 

These testosterone systems illustrate two different approaches to solve the problem of inadequate percutaneous absorption rate. In the former case, the patch must be applied to the body s most permeable skin site, the scrotum (which has been shown to be at least five times more permeable than ary other site). In the latter, the difficulty is resolved by creating a transdermal formulation which includes excipients to reduce barrier function. Neither solution is ideal scrotal application is clearly not preferred from a patient compliance standpoint on the other hand, permeation enhancers, by their very nature, tend to be irritating (and the more effective they are, the greater the irritation they provoke). This general problem, which presently limits the application of transdermal delivery, is now discussed in more detail. 

A transdermal delivery system has been developed for prevention of motion sickness and vomiting, using an adhesive patch for postauricular application the drug is released at a uniform rate for 72 hours. The adverse effects of this formulation are qualitatively typical of those reported for the oral and parenteral formulations of hyoscine and its congeners, although comparative studies suggest that the incidence is reduced with transdermal administration. Nevertheless, adverse effects involving the central nervous system, vision, bladder, and skin have been described, as have withdrawal symptoms after the patch is removed. 

The formulation additives strongly impact on transdermal delivery as the variety of dosage forms, such as creams, ointments, lotions, gels, and patches offer a wide variety of formulation additives. The problems related to the crystallization of drugs, as discussed tmder suspension dosage forms, also apply here... 

Dosages and routes of administration For acute (postoperative) pain and for anesthesia, fentanyl is given by the intravenous route. For pre-medication in anesthesia and for break-through pain the compound can also been given as an oral-transmucosal formulation (Ashburn and Streisand, 1994). A transdermal patch has been developed for chronic pain treatment (Jeal and Benfield, 1997 O Siordin, 1998). The intravenous doses for premedication are 50-100 pg, oral-transmucosal systems contain 200-400 pg and patch formulations have a delivery rate of 25-100 pg/h. 

Within the last 10, years several new compounds were launched in the field of non-steroidal antiinflammatory drugs (NSAIDs) with a clear focus on cyclooxygenase type 2 selective compounds. In the field of opioids on the other hand no new drugs have passed phase III clinical trials. In this field innovation has been achieved through new pharmaceutical formulations of known drugs such as transdermal systems, e.g. buprenorphine patch, transmucosal systems, e.g. fentanyl lollipop, or rectal delivery systems containing e.g. morphine. These were developed in order to reduce opioid side effects, but also to overcome pharmacokinetical limitations, in particular to prolong compliance and duration of action. 

M, whose experience in adhesive technology has been put to use in the transdermal field, has similarly built on its adhesive expertise in the development of a proprietary mucosal patch formulation (Cydot), which has demonstrated considerable potential for oral transmucosal delivery. The pill-sized patch uses a new bioadhesive which sticks to the gum, the cheek or the lip without causing irritation and is designed to deliver drugs for short and extended periods (up to 24 h). The small size, 0.5 to 3 cm2, helps patient compliance significantly. 

The seven dmgs and the combination estrogen-progestin product presently approved in the US for delivery by the transdermal route were all well known and available in more conventional dosage forms before their formulation into skin patches . All of these dmgs are extremely potent, none requiring more than about 20 mg per day (and some, much less) for effective therapy. 

---